Serum Factors in Primary Podocytopathies

Area of Science:

• Nephrology
• Immunology

Background:

• Primary podocytopathies, including minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), are linked to circulating factors damaging podocytes.
• Treatment responsiveness suggests an immunologic basis, with therapies targeting T-cells and B-cells showing efficacy.

Purpose of the Study:

• To review evidence for both non-antibody and antibody-mediated circulating factors in primary podocytopathies.
• To explore the role of autoantibodies in disease pathogenesis and recurrence post-transplantation.

Main Methods:

• Review of existing literature on circulating factors and podocytopathy pathogenesis.
• Analysis of data on immunosuppressive therapies, including rituximab.
• Discussion of findings from high-resolution confocal microscopy and antibody detection.

Main Results:

• Non-antibody factors like cardiotrophin-like cytokine 1 have been identified.
• Emerging evidence points to autoantibodies, particularly anti-nephrin antibodies, as a significant cause.
• Circulating antibodies correlate with disease recurrence after kidney transplantation.

Conclusions:

• Autoantibodies targeting podocyte structures are increasingly implicated in primary podocytopathies.
• Understanding the specific pathogenic factor, whether antibody or non-antibody mediated, may inform individualized treatment approaches.